Safety considerations with new treatment regimens for anal cancer

References

• Cancer STAT facts: anal cancer [Internet]. Bethseda (MD): National Cancer Institute Surveillance, Epidemiology, and End Results Program; [ cited 2020 Nov 4]. Available from: https://seer.cancer.gov/statfacts/html/anus.html
   Google Scholar
• Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270–280.
   PubMed Web of Science ®Google Scholar
• Tseng H, Morgenstern H, Mack TM, et al. Risk factors for anal cancer: results of a population-based case-control study. Cancer Causes Control. 2003;14(9):837–846.
   PubMed Web of Science ®Google Scholar
• Sunesen KG, Norgaard M, Thorlacius-Ussing O, et al. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978–2005. Int J Cancer. 2010;127(3):675–684.
   PubMed Web of Science ®Google Scholar
• Nilsson MP, Nilsson EP, Johnsson A, et al. Patterns of recurrence in anal cancer: a detailed analysis. Radiation Oncol. 2020;15:125.
   PubMed Web of Science ®Google Scholar
• Bowman BM, Moertel CG, O’Connell MJ, et al. Carcinoma of the anal canal. a clinical and pathologic study of 188 cases. Cancer. 1984;54(1):114–125.
   PubMed Web of Science ®Google Scholar
• Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17:354–356.
   PubMed Web of Science ®Google Scholar
• Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol. 1997;15:2040–2049.
   PubMed Web of Science ®Google Scholar
• Northover J, Glynee-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomized UKCCCR Anal Cancer Trial (ACT I). Cr J Cancer. 2010;102:1123–1128.
   PubMed Web of Science ®Google Scholar
• Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–2539.
   PubMed Web of Science ®Google Scholar
• James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomized, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14:516–524.
   PubMed Web of Science ®Google Scholar
• Anal Carcinoma Version 02.2020 [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; [ cited 2020 Nov 24]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf.
   Google Scholar
• Rao S, Sclafani F, Eng C, et al. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: interAAct. J Clin Oncol. 2020;38:2510–2518.
   PubMed Web of Science ®Google Scholar
• Eng C, Chang GJ, You YN, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014;5(22):11133–11142.
   PubMedGoogle Scholar
• Mondaca S, Chatila WK, Bates D, et al. FOLCIS treatment and genomic correlates of response in advanced anal squamous cell cancer. Clin Colorectal Cancer. 2019;18:e39–e52.
   PubMed Web of Science ®Google Scholar
• Matsunaga M, Miwa K, Oka Y, et al. Successful treatment of metastatic anal canal adenocarcinoma with mFOLFOX6 + bevacizumab. Case Rep Oncol. 2016;9:249–254.
   PubMed Web of Science ®Google Scholar
• Kim S, Jary M, Mansi L, et al. DCF (docetaxel, cisplatin, and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol. 2013;24:3045–3050.
   PubMed Web of Science ®Google Scholar
• Morris VK, Rashid A, Rodriguez-Bigas M, et al. Clinicopathologic features associated with human papillomavirus/p16 in patients with metastatic squamous cell carcinoma of the anal canal. Oncologist. 2015 Nov;20(11):1247–1252.
   PubMed Web of Science ®Google Scholar
• Gilbert DC, Serup-Hansen E, Linnemann D, et al. Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. Br J Cancer. 2016;114(2):134–137.
   PubMed Web of Science ®Google Scholar
• Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicenter, single-arm, phase 2 study. Lancet Oncol. 2017:446–456.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Cassier PA, Fakih M, et al. Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): results from the multicohort, phase II KEYNOTE-158 study [abstract]. J Clin Oncol. 2020;38(no.4_suppl):Abstract 1.
   Web of Science ®Google Scholar
• Fluorouracil injection, for intravenous use [Package Insert]. Sagent Pharmaceuticals; 2017.
   Google Scholar
• Kadoyama K, Miki I, Tamura T, et al. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int J Med Sci. 2012;9(1):33–39.
   PubMed Web of Science ®Google Scholar
• Xeloda® (capecitabine) tablets, for oral use [Package insert]. Genentech, Inc; 2019.
   Google Scholar
• Mitomycin for injection, USP [Package insert]. Bedford Laboratories; 2013.
   Google Scholar
• Mitomycin. Lexi-drugs. Hudson, OH: Lexicomp; November 24, 2020 [cited 2020 Nov 25]. Available from: http://online.lexi.com/.
   Google Scholar
• Cisplatin injection [Package insert]. Fresenius Kabi; 2015.
   Google Scholar
• Cisplatin. Lexi-drugs. Hudson, OH: Lexicomp. November 8, 2020 [cited 2020 Nov 25]. Available from: http://online.lexi.com/.
   Google Scholar
• Carboplatin injection, solution [Package insert]. Hospira, Inc; 2018.
   Google Scholar
• Oxaliplatin injection for intravenous use [Package insert]. Hospira, Inc; 2020.
   Google Scholar
• Paclitaxel injection, USP [Package insert]. Hospira, Inc; 2018.
   Google Scholar
• Taxotere® (docetaxel) injection, for intravenous use [Package insert]. Sanofi-aventis; 2020.
   Google Scholar
• Opdivo® (nivolumab) injection, for intravenous use [Package insert]. Bristol-Myers Squibb; 2020.
   Google Scholar
• Keytruda® (pembrolizumab) injection, for intravenous use [Package insert]. Merck & Co., Inc; 2020.
   Google Scholar
• Dell’Acqua V, Surgo A, Arculeo S, et al. Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy. Int J Colorectal Dis. 2020;35(4):685–694.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter KA, Gunderson LL, et al. Intergroup RTOG 98-11: a phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. J Clin Oncol. 2006;24(18_suppl):4009.
   Web of Science ®Google Scholar
• Kouzy R, Jaoude JA, Lin D, et al. Patient-reported GI outcomes in patients with anal cancer receiving modern chemoradiation. JCO Oncol Pract. 2020;16.
   PubMedGoogle Scholar
• Koh HK, Kim K, Jang W, et al. Radiation therapy for anal squamous cell carcinoma: a retrospective multicenter study. Anticancer Res. 2018;38(12):6931–6938.
   PubMed Web of Science ®Google Scholar
• Ghareeb A, Paramasevon K, Mokool P, et al. Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy. Ann R Coll Surg Engl. 2019;101(3):168–175.
   PubMed Web of Science ®Google Scholar
• De Meric De Bellefon M, Lemanski C, Castan F, et al. Long-term follow-up experience in anal canal cancer treated with intensity-modulated radiation therapy: clinical outcomes, patterns of relapse and predictors of failure. Radiother Oncol. 2020;144:141–147.
   PubMed Web of Science ®Google Scholar
• Wallington DG, Holliday EB. Preparing patients for sexual dysfunction after radiation for anorectal cancers: a systematic review. Pract Radiat Oncol. 2020. DOI:https://doi.org/10.1016/j.prro.2020.07.007
   Google Scholar
• Press release: tarveda therapeutics reports complete data from phase 1 portion of phase 1/2a study of PEN-866 to be presented at the ASCO20 virtual scientific program [Internet]. Watertown (MA): Tarveda Therapeutics; [ cited 2020 Nov 10]. Available from: https://www.tarvedatx.com/5-13-20-tarveda-therapeutics-reports-complete-data-from-phase-1-portion-of-phase-1/2a-study-of-pen-866-to-be-presented-at-the-asco20-virtual-scientific-program
   Google Scholar
• Falchook GS, Bendell JC, Ulahannan SV, et al. Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: phase I and expansion cohort results [abstract]. J Clin Oncol. 2020;38(15):3515.
   Web of Science ®Google Scholar
• Proia DA, Smith DL, Zhang J, et al. HSP90 inhibitor–SN-38 conjugate strategy for targeted delivery of topoisomerase I inhibitor to tumors. Mol Cancer Ther. 2015;14(11):2422–2432.
   PubMed Web of Science ®Google Scholar
• Camptosar® (irinotecan) injection, for intravenous use [Package insert]. Pfizer. 2020.
   Google Scholar
• Imfinzi® (durvalumab) injection, for intravenous use [Package insert]. AstraZeneca. 2020.
   Google Scholar
• Lakhani N, Mehnert JM, Rasco D, et al. A phase 1 study of the safety, tolerability, and pharmacokinetics (PLK) of MGA012 (anti-PD-1 antibody) in patients with advanced solid tumors [poster]. Presented at the Society for Immunotherapy of Cancer (STIC) 32nd Annual Meeting, 2017. National Harbor, MD. Available at: https://www.macrogenics.com/wp-content/wbuploads/wb_publications/SITC-2017-MGA012-PD-1-Ph.-1-Study-of-Safety-Tolerability-and-PK.pdf. Accessed 2020 Nov 25
   Google Scholar
• Mehnert JM, Joshua AM, Lakhani N, et al. First-in-human phase 1 study of INCMGA00012 in patients with advanced solid tumors: interim results of the cohort expansion phase [poster]. Presented at the Society for Immunotherapy of Cancer (STIC) 33rd Annual Meeting, 2018. Washington, DC. Available at: https://www.macrogenics.com/wp-content/wbuploads/wb_publications/SITC-2018-P669-MGA012-Ph-1-Cohort-Expansion.pdf. Accessed 2020 Nov 25
   Google Scholar
• Yervoy® (ipilimumab) injection, for intravenous use [Package insert]. Bristol Myers Squibb. 2020.
   Google Scholar
• Hasan Y, Furtado L, Tergas A, et al. A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys. 2020;107(3):487–498.
   PubMed Web of Science ®Google Scholar
• Kymriah® (tisagenlecleucel) suspension for injection [Package insert]. Novartis. 2018.
   Google Scholar
• Yescarta® (axicabtagene ciloleucel) suspension for intravenous infusion [Package insert]. Kite Pharma. 2020.
   Google Scholar
• Erbitux® (cetuximab) injection, for intravenous use [Package insert]. Eli Lilly and Company. 2020.
   Google Scholar
• Vectibix® (panitumumab) injection for intravenous use [Package insert]. Amgen Inc. 2017.
   Google Scholar
• Capelli L, Gardini AC, Scarpi E, et al. No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). Sci Rep. 2016;6:37621.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–1127.
   PubMed Web of Science ®Google Scholar
• Garg MK, Zhao F, Sparano JA, et al. Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II eastern cooperative oncology group-American college of radiology imaging network cancer research group trial (E3205). J Clin Oncol. 2017;35(7):718–726.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee JY, Palefsky J, et al. Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS Malignancy Consortium trial. J Clin Oncol. 2017;35(7):727–733.
   PubMed Web of Science ®Google Scholar
• Olivatto LO, Vieira FM, Pereira BV, et al. Phase I study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer. 2013;119(16):2973–2980.
   PubMed Web of Science ®Google Scholar
• Feliu J, Garcia-Carbonero R, Capdevila J, et al. VITAL phase 2 study: upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02). Cancer Med. 2020;9(3):1008–1016.
   PubMed Web of Science ®Google Scholar
• Rogers JE, Aaa J, Ohinata A, et al. Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. Expert Rev Anticancer Ther. 2020;20(10):901–908.
   PubMed Web of Science ®Google Scholar
• Saif MW, Kontny E, Syrigos KN, et al. The role of EGFR inhibitors in the treatment of metastatic anal canal carcinoma: a case series. J Oncol. 2011;2011:125467.
   PubMedGoogle Scholar
• Kim DW, Byer J, Kothari N, et al. EGFR inhibitors in patients with advanced squamous cell anal carcinomas: a single-institution experience. Oncology. 2017;92:190–196.
   PubMed Web of Science ®Google Scholar
• Gancz D, Fishelson Z. Cancer resistance to complement dependent cytotoxicity (CDC): problem-oriented research and development. Mol Immunol. 2009;46:2794–2800.
   PubMed Web of Science ®Google Scholar
• Bakema JE, Van Egmond M. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Curr Top Microbiol Immunol. 2014;382:373–392.
   PubMed Web of Science ®Google Scholar
• Lonardi S, Pietrantonio F, Prete AA, et al. Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: the CARACAS study. J Clin Oncol. 2020;38(15):Abstract 4051.
   Google Scholar
• Martin D, Balermpas P, Gollrad J, et al. RADIANCE- Radiochemotherapy with or without durvalumab in the treatment of anal squamous cell carcinoma: a randomized multicenter phase II trial. Clin Transl Radiat Oncol. 2020;23:43–49.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. N Engl J Med. 2017;377:1919–1929.
   PubMed Web of Science ®Google Scholar
• NCT04230759. Radiochemotherapy ± durvalumab for locally-advanced anal carcinoma. A multicenter, randomized, phase II trial of the German anal cancer study group (RADIANCE) [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT04230759
   Google Scholar
• NCT04046133. Phase 1b/II trial of pembrolizumab plus IMRT in stage III/IV carcinoma of anus (CORINTH) [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT04046133
   Google Scholar
• NCT03233711. Nivolumab after combined modality therapy in treating patients with high risk stage II-IIIb anal cancer [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03233711
   Google Scholar
• Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28:690–714.
   PubMed Web of Science ®Google Scholar
• NCT04444921. Testing the addition of nivolumab to chemotherapy for patients with metastatic anal cancer [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT04444921
   Google Scholar
• NCT04472429. Carboplatin-paclitaxel with retifanlimab or placebo in participants with locally advanced or metastatic squamous cell anal carcinoma (POD1UM-303/InterAACT 2) [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT04472429
   Google Scholar
• Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25–39.
   PubMed Web of Science ®Google Scholar
• NCT02314169. Nivolumab with or without ipilimumab in treating patients with refractory metastatic anal canal cancer [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02314169
   Google Scholar
• NCT03517488. A study of XmAb®20717 in subjects with selected advanced solid tumors (DUET-2) [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03517488
   Google Scholar
• XmAb20717 [Internet]. Monrovia (CA): Xencor; [ cited 2020 Nov 15]. Available from: https://www.xencor.com/pipeline/xmab20717/
   Google Scholar
• Hickingbotton M, Clynes R, Desjarlais J, et al. Preliminary safety and pharmacodynamic (PD) activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in a phase I dose escalation study of patients with selected advanced solid tumors [abstract]. J Clin Oncol. 2020;38(15):e15001.
   Web of Science ®Google Scholar
• Shum E, Daud A, Reilley M, et al. Preliminary safety, pharmacokinetics/ pharmacodynamics,and antitumor activity of XMAB20717, a PD-1 X CTLA-4 bispecific antibody, in patients with advanced solid tumors [abstract]. J Immunother Cancer. 2020;8(Suppl 3):A407.
   Google Scholar
• Strauss J, Gatti-Mays ME, Cho B, et al. Abstract CT075: phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-ß and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies [abstract]. Proceedings: AACR Annual Meeting. 2019;79(13):CT075.
   Google Scholar
• Levovitz C, Chen D, Ivansson E, et al. TGFß receptor 1: an immune susceptibility gene in HPV-associated cancer. Cancer Res. 2014;74(23):6833–6844.
   PubMed Web of Science ®Google Scholar
• Gatti-Mays ME, Gulley JL. M7824: a promising new strategy to combat cancer immune evasion. Oncoscience. 2018;5(11–12):269–270.
   PubMedGoogle Scholar
• Press releases. Merck KGaA, Darmstadt, Germany and GSK announce global alliance to jointly develop and commercialize M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers [Internet]. Darmstadt (DE): Merck KGaA, Darmstadt, Germany; [ cited 2020 Nov 16]. Available from: https://www.emdgroup.com/en/news/m7824-2019-02-05.html
   Google Scholar
• Bang Y-J, Doi T, Kondo S, et al. Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-ß, in patients with pretreated recurrent or refractory gastric cancer [abstract]. Ann Oncol. 2018;29(8):VIII222–VIII223.
   Google Scholar
• Paz-Ares L, Kim TM, Vincente D, et al. Updated results of M7824 (MSB0011359C): a bifunctional fusion protein targeting TGF-ß and PD-L1, in second-line (2L) NSCLC [abstract]. Ann Oncol. 2018;29(8):VIII259.
   Google Scholar
• Yoo C, Oh D-Y, Choi HJ, et al. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-ß, in Asian patients with pretreated biliary tract cancer: preliminary results from a phase I trial [abstract]. Ann Oncol. 2018;29(8):VIII258–VIII259.
   Google Scholar
• Spira A, Awada A, Isambert N, et al. Abstract P3-09-06: bintrafusp alfa (M7824), a bifunctional fusion protein targeting transforming growth factor-ß and programmed death ligand 1, in advanced triple-negative breast cancer: preliminary results from a phase 1 cohort [abstract]. proceedings: 2019 San Antonio breast cancer symposium. Cancer Res. 2020;80(4Suppl):P3-09-06.
   Google Scholar
• NCT03427411. M7824 in subjects with HPV associated malignancies [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03427411
   Google Scholar
• NCT04432597. HPV vaccine PRGN-2009 alone or in combination with anti-PDL1/TGF-beta trap (M7824) in subjects with HPV associated cancers [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT04432597
   Google Scholar
• Rumfield CS, Roller N, Pellom ST, et al. Therapeutic vaccines for HPV-associated malignancies. Immunotargets Ther. 2020;2020(9):167–200.
   Google Scholar
• Miles BA, Monk BJ, Safran SP. Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy. Gynecol Oncol Res Pract. 2017;9:1–12.
   Google Scholar
• Pellom ST, Rumfield CS, Morillon YM, et al. Anti-tumor efficacy and immune responses induced by a novel therapeutic HPV-specific gorilla adenovirus off-the-shelf immunotherapeutic (PRGN-2009) [abstract]. J Immunol. 2020;204(1 Supplement):91.6.
   Web of Science ®Google Scholar
• Rumfield CS, Pellom ST, Morillon IIYM, et al. Immunomodulation to enhance the efficacy of an HPC therapeutic vaccine. J Immunother Cancer. 2020;8:e000612.
   PubMed Web of Science ®Google Scholar
• Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines. 2014;2(6):159–182.
   PubMedGoogle Scholar
• Bedu-Addo F, Conn G, King M, et al. An open-label phase I/IIa escalating dose study to evaluate safety and T cell immunogenicity of PDS0101 in subjects with cervical intraepithelial neoplasia (CIN) and high-risk HPV infection [abstract]. J Immunother Cancer. 2016;4(Suppl 2).
   Google Scholar
• NCT04287868. Combination immunotherapy in subjects with advances HPV associated malignancies [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT04287868
   Google Scholar
• Aggarwal C, Cohen RB, Morrow MP, et al. Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer. Clin Cancer Res. 2019;25(1):110–124.
   PubMed Web of Science ®Google Scholar
• Hobernik D, Bros M. DNA vaccines- how far from clinical use? Int J Mol Sci. 2018;19(11):3605.
   Web of Science ®Google Scholar
• Aggarwal C, Saba NF, Algazi AP, et al. 916MO safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HOV+ R/M HNSCC) [abstract]. Annals Oncol. 2020;31(Suppl 4):S661–S662.
   PubMedGoogle Scholar
• NCT03439085. DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and durvalumab in treating patients with recurrent or metastatic human papillomavirus associated cancers [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT03439085
   Google Scholar
• NCT01671488. A phase I/II evaluation of ADXS11-001, mitomycin, 5-fluorouracil (5-FU) and IMRT for anal cancer (276) [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT01671488
   Google Scholar
• Huh WK, Dizon DS, Powell MA, et al. ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: results from stage I of the phase II GOG/NRG0265 study [abstract]. J Clin Oncol. 2016;34(15): Abstract 5516.
   Web of Science ®Google Scholar
• Basu P, Mehta A, Jain M, et al. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer [abstract]. Int J Gynecol Cancer. 2018;28(4):764–772.
   PubMed Web of Science ®Google Scholar
• Safran H, Leonard KL, Perez K, et al. Tolerability of ADXS11-001 Lm-LLO Listeria-based immunotherapy with mitomycin, fluorouracil, and radiation for anal cancer [abstract]. Int J Radiat Oncol Biol Phy. 2018;100(5):1175–1178.
   PubMed Web of Science ®Google Scholar
• Eng C, Fakih M, Amin M, et al. A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget. 2020;11:1334–1343.
   PubMedGoogle Scholar
• Search orphan drug designations and approvals [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; [ cited 2020 Nov 19]. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=401813
   Google Scholar
• CD4-specific telomerase peptide vaccine UCPVax [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 18]. Available from: https://www.ncbi.nlm.nih.gov/medgen/1382601
   Google Scholar
• Negrini S, De Palma R, Filaci G. Anti-cancer immunotherapies targeting telomerase. Cancers (Basel). 2020;12(8):2260.
   Web of Science ®Google Scholar
• UCPVax: a UCP vaccine enhancing CD4+ response [Internet]. Houston (TX): Invectys USA; [ cited 2020 Nov 18]. Available from: https://www.invectys.com/products-pipeline/ucpvax-a-ucp-vaccine-enhancing-cd4-response/
   Google Scholar
• Laheurte C, Dosset M, Vernerey D, et al. Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. Br J Cancer. 2019;121:405–416.
   PubMed Web of Science ®Google Scholar
• NCT02818426. Universal cancer peptide-based vaccination in metastatic NSCLC (UCPVax) [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT02818426
   Google Scholar
• Berry J, Gralgow SC. Vaccinations for anal squamous cancer: current and emerging therapies. Clin Colon Rectal Surg. 2018;31:321–327.
   PubMed Web of Science ®Google Scholar
• NCT03946358. Combination of UCPVax vaccine and atezolizumab for the treatment of human papillomavirus positive cancer (VolATIL) [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT03946358
   Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73.
   PubMed Web of Science ®Google Scholar
• Doran SL, Stevanovic S, Adhikary S, et al. T-cell receptor gene therapy for human papillomavirus–associated epithelial cancers: a first-in-human, phase I/II study. J Clin Oncol. 2019;37(30):2759–2768.
   PubMed Web of Science ®Google Scholar
• NCT02379520. HPV-16/18 E6/E7-specific lymphocytes, relapsed HPV-associated cancers, HESTIA [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Nov 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02379520
   Google Scholar
• NCT04084951. Study of SQZ-PBMC-HPV in patients with HPV16+ recurrent, locally advanced or metastatic solid tumors [Internet]. Bethesda (MD): National Institutes of Health; [ cited 2020 Dec 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT04084951
   Google Scholar
• Developing products for rare diseases and conditions [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; [ cited 2020 Nov 24]. Available from: https://www.fda.gov/industry/developing-products-rare-diseases-conditions
   Google Scholar